TESARO Inc (NASDAQ:TSRO) – Leerink Swann issued their FY2021 earnings per share estimates for TESARO in a research report issued on Tuesday, October 16th. Leerink Swann analyst A. Berens forecasts that the biopharmaceutical company will post earnings of ($2.99) per share for the year. Leerink Swann has a “Outperform” rating and a $48.00 price objective on the stock. Leerink Swann also issued estimates for TESARO’s FY2022 earnings at ($0.09) EPS.
Several other research firms have also weighed in on TSRO. Cann reissued a “buy” rating and set a $83.00 price objective on shares of TESARO in a research note on Tuesday, September 4th. HC Wainwright reduced their price objective on shares of TESARO to $71.00 and set a “buy” rating on the stock in a research note on Friday, July 20th. Zacks Investment Research raised shares of TESARO from a “sell” rating to a “hold” rating in a research note on Tuesday, July 17th. Guggenheim began coverage on shares of TESARO in a research note on Monday, September 17th. They set a “buy” rating on the stock. Finally, BidaskClub raised shares of TESARO from a “hold” rating to a “buy” rating in a research note on Friday, October 5th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and fifteen have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $78.42.
TESARO (NASDAQ:TSRO) last issued its earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($3.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.66) by ($0.38). The business had revenue of $57.21 million during the quarter, compared to the consensus estimate of $65.50 million. TESARO had a negative net margin of 180.29% and a negative return on equity of 285.30%. The firm’s revenue for the quarter was up 94.2% compared to the same quarter last year. During the same period last year, the business posted ($2.82) EPS.
Several hedge funds and other institutional investors have recently bought and sold shares of TSRO. Schwab Charles Investment Management Inc. raised its holdings in shares of TESARO by 4.3% in the first quarter. Schwab Charles Investment Management Inc. now owns 113,991 shares of the biopharmaceutical company’s stock valued at $6,514,000 after purchasing an additional 4,652 shares during the last quarter. Northern Trust Corp increased its holdings in TESARO by 14.1% during the first quarter. Northern Trust Corp now owns 248,855 shares of the biopharmaceutical company’s stock worth $14,219,000 after buying an additional 30,828 shares during the last quarter. Russell Investments Group Ltd. increased its holdings in TESARO by 54.1% during the first quarter. Russell Investments Group Ltd. now owns 8,498 shares of the biopharmaceutical company’s stock worth $485,000 after buying an additional 2,985 shares during the last quarter. Stifel Financial Corp acquired a new position in TESARO during the first quarter worth $241,000. Finally, Commonwealth Equity Services LLC increased its holdings in TESARO by 93.9% during the first quarter. Commonwealth Equity Services LLC now owns 12,675 shares of the biopharmaceutical company’s stock worth $724,000 after buying an additional 6,139 shares during the last quarter.
In other TESARO news, Director Arnold L. Oronsky sold 10,000 shares of TESARO stock in a transaction that occurred on Tuesday, August 7th. The shares were sold at an average price of $26.77, for a total value of $267,700.00. Following the transaction, the director now owns 12,479 shares of the company’s stock, valued at $334,062.83. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In the last ninety days, insiders sold 10,630 shares of company stock worth $290,424. Insiders own 33.70% of the company’s stock.
Tesaro, Inc, an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States. It offers ZEJULA (niraparib), an orally active and potent poly polymerase inhibitor for the maintenance treatment of women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer; and VARUBI (rolapitant), a neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting.
Recommended Story: How accurate is the Rule of 72?
Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.